A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors
Stopped early · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
This is a multicenter, open-label, Phase 1 study of orally administered CB-5083 in adult subjects with advanced metastatic solid tumors. The study will be conducted in 2 parts: an initial Dose Escalation Phase (Phase 1a) of CB-5083 in subjects with advanced metastatic solid tumors who have progressed or are non-responsive to available therapies and for which no standard therapy exists, followed by a Dose Expansion Phase (Phase 1b) which will include 1 to 4 arms: one arm in subjects with RAS mutated mCRC; optionally, at sponsors discretion, 3 additional arms may be added for subjects with advanced RCC, advanced pNET, or solid tumors with mutations in the RAS-MAPK pathway.
Key facts
- Study ID
- NCT02243917
- Run by
- Cleave Biosciences, Inc.
- People needed
- 62
- Starts
- 2014-10-11
- Expected to finish
- 2017-08-25
- Last updated by the study team
- 2018-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States
- University of California San Francisco — San Francisco, California, United States
- University of Colorado — Aurora, Colorado, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.